Teladoc Health Q1 revenue +3% to $646.1M; adjusted EBITDA +20% to $63.1M

Teladoc Health, Inc.

2024-Q1 EPS reported -$0.49 revenue$646,131,000

Revenue $646.1M (+3% YoY); net loss $81.9M ($0.49 EPS) vs $69.2M loss in Q1 2023.
Integrated Care revenue +8% to $377.1M; BetterHelp revenue -4% to $269.0M.
Adjusted EBITDA rose 20% to $63.1M; free cash flow -$26.6M (improved from -$32.5M).
Q2 2024 outlook: revenue $635-660M, adj. EBITDA $70-80M, net loss per share ($0.45)-($0.35).
Full-year 2024 outlook: revenue $2,635-2,735M, adj. EBITDA $350-390M, FCF $210-240M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Teladoc Health, Inc. reported three months ended March 31, 2024 results: revenue $646.1 million, net income $81.9 million net loss, EPS $0.49 per share. Guidance reaffirmed.

Period: three months ended March 31, 2024
Revenue: $646.1 million
Net income: $81.9 million net loss
EPS: $0.49 per share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

the three months ended March 31, 2023 (“First Quarter 2023”). Financial and Operational Highlights for First Quarter 2024 • First Quarter 2024 revenue grows 3% year-over-year to $646.1 million • First Quarter 2024 net loss of $81.9 million, or $0.49 per share • First Quarter 2024 adjusted EBITDA of $63.1 million, up 20% year-over-year “We are pleased to report a solid

View on SEC.gov

1436 earnings releases filed in the last 30 days. Browse all earnings releases →

Teladoc Health, Inc. filing history →

Source: SEC EDGAR

accession 0001477449-24-000099

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.